Anzeige
Mehr »
Donnerstag, 31.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNQR | ISIN: SE0015504097 | Ticker-Symbol: 8LY
Frankfurt
30.07.25 | 08:08
0,580 Euro
+3,02 % +0,017
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOZENGE AB Chart 1 Jahr
5-Tage-Chart
ONCOZENGE AB 5-Tage-Chart

Aktuelle News zur ONCOZENGE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiOncoZenge AB: OncoZenge Provides Market and Strategy Update298OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed...
► Artikel lesen
ONCOZENGE Aktie jetzt für 0€ handeln
21.07.OncoZenge AB: OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge Phase 3 Project71OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions ("Meribel," formerly Recipharm) as its Contract Development and Manufacturing Organization (CDMO)...
► Artikel lesen
17.07.OncoZenge AB: OncoZenge and Molteni Farmaceutici Sign Amendment to Focus BupiZenge Phase 3 Project in Europe81OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the signing of an amendment to the license and supply agreement with Molteni Farmaceutici. This amendment accelerates certain milestones...
► Artikel lesen
11.07.OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical77OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the initial investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor"). On January 27, 2025...
► Artikel lesen
09.07.OncoZenge AB Enters into Convertible Loan Agreement with Linc AB1
08.07.OncoZenge AB: OncoZenge Appoints Tuulikki Lindmark as Head of CMC in Phase 3 Sponsor Team189OncoZenge AB (publ) ("OncoZenge" or "the Company") announces today that the sponsor team for the phase 3 project with BupiZenge is strengthened by the addition of Tuulikki Lindmark, who joins the Company...
► Artikel lesen
27.06.ONCOZENGE AB: OncoZenge: Investor Receives State Administration of Foreign Exchange (SAFE) Approval1
25.06.ONCOZENGE AB: OncoZenge Presents Phase 3 Study Design at MASCC/ISOO 2025 Annual Meeting1
05.06.ONCOZENGE AB: OncoZenge: Investor Receives Department of Commerce Approval1
03.06.ONCOZENGE AB: OncoZenge Appoints LINK Medical to Execute Phase 3 Feasibility Study in Europe1
30.05.ONCOZENGE AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment3
12.05.OncoZenge AB: Investor Receives NDRC Approval192OncoZenge AB (publ) ("OncoZenge" or the "Company") has today received confirmation that the NDRC has issued a certificate of approval for the investment agreement entered into by the Company and Sichuan-Yangtian...
► Artikel lesen
25.04.ONCOZENGE AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment1
11.04.OncoZenge AB: OncoZenge enters licensing agreement with Avernus Pharma for BupiZenge in the GCC Region220 OncoZenge AB (publ) ["OncoZenge" or the "Company"] announces that the Company and Avernus Pharma General Trading LLC ("Avernus"), a pharma marketing company from the UAE, have signed an exclusive agreement...
► Artikel lesen
11.04.ONCOZENGE AB: OncoZenge receives milestone payment from Molteni1
04.04.ONCOZENGE AB: OncoZenge Strengthens Phase 3 Sponsor Team for Regulatory Affairs1
02.04.ONCOZENGE AB: OncoZenge presents BupiZenge Phase 3 abstract at leading supportive cancer care conference in the US in June2
28.03.OncoZenge AB: OncoZenge AB enters exclusive agreement with Molteni Farmaceutici for commercialization of BupiZenge in Europe111OncoZenge AB (publ) ("OncoZenge" or the "Company") announces that the Company has entered into a binding agreement to partner with L. Molteni & C. dei F.lli Alitti, Società di Esercizio S.p.A ("Molteni...
► Artikel lesen
04.03.OncoZenge AB: OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge153Stockholm, March 4, 2025 - OncoZenge AB (publ) announces today that a positive opinion has been received regarding the patentability of the new international application submitted to the PCT (Patent...
► Artikel lesen
13.01.OncoZenge AB: OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge in Europe117STOCKHOLM, SWEDEN - January 13, 2025 - OncoZenge AB (publ) ("OncoZenge" or the "Company"), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1